Randomized clinical trial evaluating triazolopyridazine SLU-2633 as a treatment for gastric cryptosporidiosis in eastern indigo snakes (Drymarchon couperi).

Kurkumin dyker upp i denna sammanfattning bara bland behandlingar som tidigare misslyckats med att eliminera parasiten. Själva studien testade inte kurkumin. The active group received SLU-2633 at 50 mg/kg once daily for four days and then twice weekly for six weeks. The control group received diluent on the same schedule. SLU-2633 lowered C. serpentis DNA relative to control three weeks after the first dose (p=0.047), and the difference remained one month after treatment stopped (p=0.018). Two months after stopping treatment, the groups no longer differed (p=0.27). At this regimen, the compound reduced overall parasite DNA burden by 88%. Mouse findings are also described, including a 99% burden reduction after 50 mg/kg twice daily for four days, but they cannot establish effects in people. This animal infection experiment provides no evidence that curcumin benefits human health, ageing, or longevity.

SLU-2633 reduced C. serpentis DNA burden by 88% and may require an optimised dosing regimen or formulation to eliminate infection in eastern indigo snakes.